Políticas de salud y de salud mental en Brasil: la exclusión/inclusión social como intención y gesto

This study emphasizes the specific characteristics of the mental health as a health policy in the social political field, in Brazil. The objective of this study is to analyze on the Society/State/Health articulations between the structural policies and the specific politic program by means of the historical rescue of these policies, identifying the characteristics and problems at each moment. Presently, an impact between the two strategies of the psychiatric assistance is observed: the hegemonic, hospital centered model which abducts lives, mutilate bodies and minds and trade the Health and, that one, against to the predominant model, searching the rupture by criticizing the Brazilian society.Trata-se de um ensaio que focaliza as políticas de saúde mental como política de saúde no âmbito das políticas sociais no Brasil. Busca refletir as articulações entre sociedade/Estado/saúde no plano político estrutural e político específico, por meio do resgate histórico das referidas políticas, identificando as características e os problemas de cada momento.Conclui que há na atualidade, um embate entre duas estratégias de assistência psiquiátrica: a do modelo hegemônico, hospitalocéntrico, que seqüestra vidas, mutila corpos e mentes e mercantiliza a saúde, e a do modelo contra-hegemônico, que busca a ruptura pela crítica àquela lógica, para produzir a tolerância para com a diferença, na sociedade brasileira.Este es un ensayo que enfoca las políticas de salud mental como política de salud en el âmbito de las políticas sociales en Brasil. Busca reflexionar las articulaciones entre Sociedad/Estado/Salud, en el piano político estructural y político específico, por medio del rescate histórico de las referidas políticas, identificando las características y los problemas de cada momento. Concluyese que existe hoy dia, un embate entre dos estratégias de asistencia psiquiátrica: la del modelo hegemónico, hospitalocéntrico que secuestra vidas, mutila cuerpos y mentes y mercantiliza la salud; la del modelo contra-hegemónico que busca la ruptura por la crítica a aquella lógica para produzir la tolerancia para con la diferencia, en la sociedad brasileña

Role of protein kinase R in the killing of Leishmania major by macrophages in response to neutrophil elastase and TLR4 via TNF and IFN

In cutaneous leishmaniasis, Leishmania amazonensis activates macrophage double-stranded, RNA-activated protein kinase R (PKR) to promote parasite growth. In our study, Leishmania major grew normally in RAW cells, RAW-expressing dominant-negative PKR (PKR-DN) cells, and macrophages of PKR-knockout mice, revealing that PKR is dispensable for L. major growth in macrophages. PKR activation in infected macrophages with poly I:C resulted in parasite death. Fifty percent of L. major-knockout lines for the ecotin-like serine peptidase inhibitor (ISP2; Δisp2/isp3), an inhibitor of neutrophil elastase (NE), died in RAW cells or macrophages from 129Sv mice, as a result of PKR activation. Inhibition of PKR or NE or neutralization of Toll-like receptor 4 or 2(TLR4 or TLR2) prevented the death of Δisp2/isp3. Δisp2/isp3 grew normally in RAW-PKR-DN cells or macrophages from 129Sv pkr−/−, tlr2−/−, trif−/−, and myd88−/− mice, associating NE activity, PKR, and TLR responses with parasite death. Δisp2/isp3 increased the expression of mRNA for TNF-α by 2-fold and of interferon β (IFNβ) in a PKR-dependent manner. Antibodies to TNF-α reversed the 95% killing by Δisp2/isp3, whereas they grew normally in macrophages from IFN receptor–knockout mice. We propose that ISP2 prevents the activation of PKR via an NE-TLR4-TLR2 axis to control innate responses that contribute to the killing of L. major.—Faria, M. S., Calegari-Silva, T. C., de Carvalho Vivarini, A., Mottram, J. C., Lopes, U. G., Lima, A. P. C. A. Role of protein kinase R in the killing of Leishmania major by macrophages in response to neutrophil elastase and TLR4 via TNFα and IFNβ

Genome of the Avirulent Human-Infective Trypanosome—Trypanosoma rangeli

Background: Trypanosoma rangeli is a hemoflagellate protozoan parasite infecting humans and other wild and domestic mammals across Central and South America. It does not cause human disease, but it can be mistaken for the etiologic agent of Chagas disease, Trypanosoma cruzi. We have sequenced the T. rangeli genome to provide new tools for elucidating the distinct and intriguing biology of this species and the key pathways related to interaction with its arthropod and mammalian hosts.  Methodology/Principal Findings: The T. rangeli haploid genome is ,24 Mb in length, and is the smallest and least repetitive trypanosomatid genome sequenced thus far. This parasite genome has shorter subtelomeric sequences compared to those of T. cruzi and T. brucei; displays intraspecific karyotype variability and lacks minichromosomes. Of the predicted 7,613 protein coding sequences, functional annotations could be determined for 2,415, while 5,043 are hypothetical proteins, some with evidence of protein expression. 7,101 genes (93%) are shared with other trypanosomatids that infect humans. An ortholog of the dcl2 gene involved in the T. brucei RNAi pathway was found in T. rangeli, but the RNAi machinery is non-functional since the other genes in this pathway are pseudogenized. T. rangeli is highly susceptible to oxidative stress, a phenotype that may be explained by a smaller number of anti-oxidant defense enzymes and heatshock proteins.  Conclusions/Significance: Phylogenetic comparison of nuclear and mitochondrial genes indicates that T. rangeli and T. cruzi are equidistant from T. brucei. In addition to revealing new aspects of trypanosome co-evolution within the vertebrate and invertebrate hosts, comparative genomic analysis with pathogenic trypanosomatids provides valuable new information that can be further explored with the aim of developing better diagnostic tools and/or therapeutic targets

Distinct patterns of somatic alterations in a lymphoblastoid and a tumor genome derived from the same individual

Although patterns of somatic alterations have been reported for tumor genomes, little is known on how they compare with alterations present in non-tumor genomes. A comparison of the two would be crucial to better characterize the genetic alterations driving tumorigenesis. We sequenced the genomes of a lymphoblastoid (HCC1954BL) and a breast tumor (HCC1954) cell line derived from the same patient and compared the somatic alterations present in both. The lymphoblastoid genome presents a comparable number and similar spectrum of nucleotide substitutions to that found in the tumor genome. However, a significant difference in the ratio of non-synonymous to synonymous substitutions was observed between both genomes (P = 0.031). Protein–protein interaction analysis revealed that mutations in the tumor genome preferentially affect hub-genes (P = 0.0017) and are co-selected to present synergistic functions (P < 0.0001). KEGG analysis showed that in the tumor genome most mutated genes were organized into signaling pathways related to tumorigenesis. No such organization or synergy was observed in the lymphoblastoid genome. Our results indicate that endogenous mutagens and replication errors can generate the overall number of mutations required to drive tumorigenesis and that it is the combination rather than the frequency of mutations that is crucial to complete tumorigenic transformation

Distinct patterns of somatic alterations in a lymphoblastoid and a tumor genome derived from the same individual

Although patterns of somatic alterations have been reported for tumor genomes, little is known on how they compare with alterations present in non-tumor genomes. A comparison of the two would be crucial to better characterize the genetic alterations driving tumorigenesis. We sequenced the genomes of a lymphoblastoid (HCC1954BL) and a breast tumor (HCC1954) cell line derived from the same patient and compared the somatic alterations present in both. The lymphoblastoid genome presents a comparable number and similar spectrum of nucleotide substitutions to that found in the tumor genome. However, a significant difference in the ratio of non-synonymous to synonymous substitutions was observed between both genomes (P = 0.031). Protein–protein interaction analysis revealed that mutations in the tumor genome preferentially affect hub-genes (P = 0.0017) and are co-selected to present synergistic functions (P < 0.0001). KEGG analysis showed that in the tumor genome most mutated genes were organized into signaling pathways related to tumorigenesis. No such organization or synergy was observed in the lymphoblastoid genome. Our results indicate that endogenous mutagens and replication errors can generate the overall number of mutations required to drive tumorigenesis and that it is the combination rather than the frequency of mutations that is crucial to complete tumorigenic transformation

Ações do Projeto “Ações Construtivas do Conhecimento Químico” e Suas Contribuições Pedagógicas na Cidade de Manaus - AM

NESTE TRABALHO SÃO RELATADAS AS CONTRIBUIÇÕES QUE O PROJETO AÇÕES CONSTRUTIVAS DO CONHECIMENTOQUÍMICO NAS ESCOLAS PÚBLICAS TROUXE PARA A VIDA ESCOLAR DOS ESTUDANTES DO ESTADO DO AMAZONAS, SUBRETUDO EM SUA CAPITAL, MANAUS. O PROJETO ACONTECE DESDE OUTUBRO DE 2011, EM 7 ESCOLAS-SEDE, CONTEMPLANDO TODAS AS REGIÕES GEOGRÁFICAS DO MUNICÍPIO. 300 ESTUDANTES, DO PRIMEIRO E SEGUNDO ANO DO ENSINO MÉDIO, ORIUNDOS DE 20 ESCOLAS, SÃO ATENDIDOS PELO PROJETO. AS AULAS SÃO MINISTRADAS POR LICENCIANDOS E BACHARÉIS EM QUÍMICA DA UNIVERSIDADE FEDERAL DO AMAZONAS, E QUE SÃO ORIENTADOS POR SUPERVISORES LICENCIADOS E COM ATUAÇÃO NO ENSINO DE QUÍMICA. O PROJETO AINDA CONTA COM UMA COORDENAÇÃO NACIONAL E OUTRA NO AMAZONAS, COM AULAS SEMANAIS NAS ESCOLAS-SEDE E REUNIÕES DA EQUIPE NA UFAM. AS ATIVIDADES PERMITEM TRABALHAR SIMULTANEAMENTE FORMAÇÃO INICIAL E CONTINUADA DE PROFESSORES DE ENSINO MÉDIO, ALÉM DO APROFUNDAMENTO EM QUÍMICA QUE OS ALUNOS DE ENSINO MÉDIO DE TODAS AS REGIÕES DE MANAUS TÊM ACESSO. NESTE TRABALHO RELATAMOS, SOBRETUDO, O IMPACTO DAS AÇÕES NA FORMAÇÃO INICIAL DOS MONITORE

The germline mutational landscape of BRCA1 and BRCA2 in Brazil

The detection of germline mutations in BRCA1 and BRCA2 is essential to the formulation of clinical management strategies, and in Brazil, there is limited access to these services, mainly due to the costs/availability of genetic testing. Aiming at the identification of recurrent mutations that could be included in a low-cost mutation panel, used as a first screening approach, we compiled the testing reports of 649 probands with pathogenic/likely pathogenic variants referred to 28 public and private health care centers distributed across 11 Brazilian States. Overall, 126 and 103 distinct mutations were identified in BRCA1 and BRCA2, respectively. Twenty-six novel variants were reported from both genes, and BRCA2 showed higher mutational heterogeneity. Some recurrent mutations were reported exclusively in certain geographic regions, suggesting a founder effect. Our findings confirm that there is significant molecular heterogeneity in these genes among Brazilian carriers, while also suggesting that this heterogeneity precludes the use of screening protocols that include recurrent mutation testing only. This is the first study to show that profiles of recurrent mutations may be unique to different Brazilian regions. These data should be explored in larger regional cohorts to determine if screening with a panel of recurrent mutations would be effective.This work was supported in part by grants from Barretos Cancer Hospital (FINEP - CT-INFRA, 02/2010), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, 2013/24633-2 and 2103/23277-8), Fundação de Apoio à Pesquisa do Rio Grande do Norte (FAPERN), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), Ministério da Saúde, the Breast Cancer Research Foundation (Avon grant #02-2013-044) and National Institute of Health/National Cancer Institute (grant #RC4 CA153828-01) for the Clinical Cancer Genomics Community Research Network. Support in part was provided by grants from Fundo de Incentivo a Pesquisa e Eventos (FIPE) from Hospital de Clínicas de Porto Alegre, by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, BioComputacional 3381/2013, Rede de Pesquisa em Genômica Populacional Humana), Secretaria da Saúde do Estado da Bahia (SESAB), Laboratório de Imunologia e Biologia Molecular (UFBA), INCT pra Controle do Câncer and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). RMR and PAP are recipients of CNPq Productivity Grants, and Bárbara Alemar received a grant from the same agencyinfo:eu-repo/semantics/publishedVersio